Economic consequences and potential benefits

Best Practice and Research: Clinical Rheumatology

Volumn 25, Issue 4, 2011, Pages 607-624

  Fautrel, Bruno ^a   Verstappen, Suzanne M M ^b   Boonen, Annelies ^c  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biologicals; Cost effectiveness; Costs; Productivity; Rheumatoid arthritis; Utilisation

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTICLE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISABILITY; DISEASE DURATION; ECONOMIC EVALUATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; PRIORITY JOURNAL; PRODUCTIVITY; RHEUMATOID ARTHRITIS; SOCIAL SECURITY;

EID: 82955178212     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2011.10.001     Document Type: Review

References (92)

1. B. Jonsson Patient access to rheumatoid arthritis treatments European Journal of Health Economics 8 Suppl. 2 2008 S35 S38
2. B. Jonsson, G. Kobelt, and J. Smolen The burden of rheumatoid arthritis and access to treatment: uptake of new therapies European Journal of Health Economics 8 Suppl. 2 2008 S61 S86
3. G. Kobelt, and B. Jonsson The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments European Journal of Health Economics 8 Suppl. 2 2008 95 106
4. J. Lundqvist, F. Kastang, G. Kobelt, and B. Jonsson The burden of rheumatoid arthritis and access to treatment: determinants of access European Journal of Health Economics 8 Suppl. 2 2008 S87 S93
5. B. Jonsson, G. Kobelt, and J. Smolen Patient access to rheumatoid arthritis treatments European Journal of Health Economics 8 Suppl. 2 2008 S33 S34
6. M. Drummond, A. Maetzel, S. Gabriel, and L. March Towards a reference case for use in future economic evaluations of interventions in osteoarthritis Journal of Rheumatology Supplement 68 2003 26 30 (Pubitemid 37549319)
7. S. Merkesdal, J. Ruof, J.L. Huelsemann, O. Schoeffski, A. Maetzel, and W. Mau Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis Journal of Rheumatology 28 2001 657 661 (Pubitemid 32202679)
8. S.M. Verstappen, A. Boonen, H. Verkleij, J.W. Bijlsma, E. Buskens, and J.W. Jacobs Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity Annals of the Rheumatic Diseases 64 2005 1754 1760 (Pubitemid 41667151)
9. L.C. Franke, A.J. Ament, M.A. van de Laar, A. Boonen, and J.L. Severens Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis Clinical and Experimental Rheumatology 27 2009 S118 S123
10. W. Mau, J. Listing, D. Huscher, H. Zeidler, and A. Zink Employment across chronic inflammatory rheumatic diseases and comparison with the general population Journal of Rheumatology 32 2005 721 728 (Pubitemid 40524707)
11. M. Bjork, I. Thyberg, K. Rikner, I. Balogh, and B. Gerdle Sick leave before and after diagnosis of rheumatoid arthritis-a report from the Swedish TIRA project Journal of Rheumatology 36 2009 1170 1179
12. F. Xie The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis Arthritis and Rheumatism 59 2008 1027 1033 (Pubitemid 351991001)
13. B. Fautrel, and F. Guillemin Cost of illness studies in rheumatic diseases Current Opinion in Rheumatology 14 2002 121 126 (Pubitemid 34185293)
14. B. Fautrel, J.R. Penrod, and A.E. Clarke The economics of musculoskeletal diseases D.A. Isenberg, P.J. Maddison, P. Woo, D. Glass, F.C. Breedveld, Oxford textbook of rheumatology 3rd ed. 2004 285 296
15. S. Gabriel, M. Drummond, M.E. Suarez-Almazor, B. Ruff, F. Guillemin, and C. Bombardier OMERACT 5 Economics Working Group: summary, recommendations, and research agenda Journal of Rheumatology 28 2001 670 673 (Pubitemid 32202682)
16. S. Gabriel, M. Drummond, A. Maetzel, M. Boers, D. Coyle, and V. Welch OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis Journal of Rheumatology 30 2003 886 890 (Pubitemid 36402795)
17. F. Guillemin, S. Durieux, J.P. Daures, A. Lafuma, A. Saraux, and J. Sibilia Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists Journal of Rheumatology 31 2004 1297 1304 (Pubitemid 38879192)
18. G. Kobelt, A.S. Woronoff, B. Richard, P. Peeters, and J. Sany Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study Joint Bone Spine 75 2008 408 415
19. D. Aletaha, J. Funovits, and J.S. Smolen Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction Annals of the Rheumatic Diseases 70 2011 733 739
20. J.F. Fries, P. Spitz, R.G. Kraines, and H.R. Holman Measurement of patient outcome in arthritis Arthritis and Rheumatism 23 1980 137 145 (Pubitemid 10164318)
21. J.F. Fries, P.W. Spitz, and D.Y. Young The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales Journal of Rheumatology 9 1982 789 793
22. F. Wolfe A reappraisal of HAQ disability in rheumatoid arthritis Arthritis and Rheumatism 43 2000 2751 2761 (Pubitemid 32001741)
23. F. Wolfe, K. Michaud, O. Gefeller, and H.K. Choi Predicting mortality in patients with rheumatoid arthritis Arthritis and Rheumatism 48 2003 1530 1542 (Pubitemid 36682360)
24. M.F. Doran, G.R. Pond, C.S. Crowson, W.M. O'Fallon, and S.E. Gabriel Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period Arthritis and Rheumatism 46 2002 625 631 (Pubitemid 34214244)
25. G. Kobelt, L. Jonsson, P. Lindgren, A. Young, and K. Eberhardt Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis Arthritis and Rheumatism 46 2002 2310 2319
26. G. Kobelt, P. Lindgren, Y. Lindroth, L. Jacobson, and K. Eberhardt Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis Rheumatology (Oxford) 44 2005 1169 1175 (Pubitemid 41236026)
27. J. Lundkvist, F. Kastang, and G. Kobelt The burden of rheumatoid arthritis and access to treatment: health burden and costs European Journal of Health Economics 8 Suppl. 2 2008 S49 S60
28. F. Wolfe, and K. Michaud Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia Journal of Rheumatology 31 2004 695 700 (Pubitemid 38451254)
29. F. Wolfe, and K. Michaud Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity Arthritis and Rheumatism 61 2009 667 673
30. H. Radner, J.S. Smolen, and D. Aletaha Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis Rheumatology (Oxford) 50 2011 381 388
31. H. Radner, J.S. Smolen, and D. Aletaha Impact of comorbidity on physical function in patients with rheumatoid arthritis Annals of the Rheumatic Diseases 69 2010 536 541
32. A.T. Joyce, P. Smith, R. Khandker, J.M. Melin, and A. Singh Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA Journal of Rheumatology 36 2009 743 752
33. F. Wolfe, and K. Michaud Out-of-pocket expenses and their burden in patients with rheumatoid arthritis Arthritis and Rheumatism 61 2009 1563 1570
34. Socioeconomic deprivation and rheumatoid disease What lessons for the health service? ERAS Study Group correspond to the authors of the paper. Early rheumatoid arthritis study Annals of the Rheumatic Diseases 59 2000 794 799
35. T. Sokka, H. Kautiainen, T. Pincus, S. Toloza, P.G. da Rocha Castelar, and J. Lazovskis Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database Annals of the Rheumatic Diseases 68 2009 1666 1672
36. T. Sokka, H. Kautiainen, T. Pincus, S.M. Verstappen, A. Aggarwal, and R. Alten Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study Arthritis Research and Therapy 12 2010 R42
37. W.B. van den Hout, Y.P. Goekoop-Ruiterman, C.F. Allaart, J.K. de Vries-Bouwstra, J.M. Hazes, and P.J. Kerstens Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis Arthritis and Rheumatism 61 2009 291 299
38. B. Fautrel, S. Lucier, M.L. Laroche, S. Dadoun, M. Benhamou, and A. Saraux Costs for early rheumatoid arthritis patients by type of treatment in France: results from the ESPOIR cohort. EULAR 2010 2010 ROMA Ref Type: Generic
39. N. Bansback, C.A. Marra, A. Finckh, and A. Anis The economics of treatment in early rheumatoid arthritis Best Practice and Research: Clinical Rheumatology 23 2009 83 92
40. P. Emery, and M. Salmon Early rheumatoid arthritis: time to aim for remission? Annals of the Rheumatic Diseases 54 1995 944 947
41. T. Pincus Rheumatoid arthritis: a medical emergency? Scandinavian Journal of Rheumatology Supplement 100 1994 21 30
42. J.S. Smolen, D. Aletaha, J.W. Bijlsma, F.C. Breedveld, D. Boumpas, and G. Burmester Treating rheumatoid arthritis to target: recommendations of an international task force Annals of the Rheumatic Diseases 69 2010 631 637
43. M.E. Weinblatt Rheumatoid arthritis: treat now, not later! Annals of Internal Medicine 124 1996 773 774 (Pubitemid 26117929)
44. R.S. Sandhu, G.J. Treharne, K.M. Douglas, K. Cassim, A. Saratzis, and H. Piper The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting Musculoskeletal Care 4 2006 204 222
45. E. da Silva, M.F. Doran, C.S. Crowson, W.M. O'Fallon, and E.L. Matteson Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment Arthritis and Rheumatism 49 2003 216 220 (Pubitemid 36418280)
46. A. Boonen, G.A. Matricali, J. Verduyckt, V. Taelman, P. Verschueren, and A. Sileghem Orthopaedic surgery in patients with rheumatoid arthritis: a shift towards more frequent and earlier non-joint-sacrificing surgery Annals of the Rheumatic Diseases 65 2006 694 695
47. R.J. Weiss, A. Stark, M.C. Wick, A. Ehlin, K. Palmblad, and P. Wretenberg Orthopaedic surgery of the lower limbs in 49,802 rheumatoid arthritis patients: results from the Swedish National Inpatient Registry during 1987 to 2001 Annals of the Rheumatic Diseases 65 2006 335 341 (Pubitemid 43268222)
48. T. Sokka, H. Kautiainen, and P. Hannonen Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis Annals of the Rheumatic Diseases 66 2007 341 344 (Pubitemid 46579635)
49. R.J. Weiss, A. Ehlin, S.M. Montgomery, M.C. Wick, A. Stark, and P. Wretenberg Decrease of RA-related orthopaedic surgery of the upper limbs between 1998 and 2004: data from 54,579 Swedish RA inpatients Rheumatology (Oxford) 47 2008 491 494
50. S. Momohara, E. Inoue, K. Ikari, K. Kawamura, S. Tsukahara, and T. Iwamoto Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (IORRA) Annals of the Rheumatic Diseases 69 2010 312 313
51. S.M. Verstappen, J.W. Bijlsma, H. Verkleij, E. Buskens, A.A. Blaauw, and E.J. ter Borg Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys Arthritis and Rheumatism 51 2004 488 497 (Pubitemid 38725152)
52. J.M. Albers, H.H. Kuper, P.L. van Riel, M.L. Prevoo, M.A. van 't Hof, and A.M. van Gestel Socio-economic consequences of rheumatoid arthritis in the first years of the disease Rheumatology (Oxford) 38 1999 423 430 (Pubitemid 29507126)
53. S. Dadoun, S. Lucier, M. De Rosa, A. Saraux, F. Berenbaum, and L. Durand-Zaleski Rheumatoid Arthritis (RA) impact on work and RA-related indirect costs during the first three years after RA diagnosis. An economic analysis from the ESPOIR cohort 2010 ACR abstract Atlanta USA 2011.Ref Type: Generic
54. E. Yelin, L. Trupin, P. Katz, D. Lubeck, S. Rush, and L. Wanke Association between etanercept use and employment outcomes among patients with rheumatoid arthritis Arthritis and Rheumatism 48 2003 3046 3054 (Pubitemid 37409314)
55. S.M. Verstappen, K.D. Watson, M. Lunt, K. McGrother, D.P. Symmons, and K.L. Hyrich Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology (Oxford) 49 2010 1570 1577
56. S. Allaire, F. Wolfe, J. Niu, Y. Zhang, B. Zhang, and M. LaValley Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out Arthritis and Rheumatism 59 2008 1082 1089
57. J.M. Hazes, P. Taylor, V. Strand, O. Purcaru, G. Coteur, and P. Mease Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol Rheumatology (Oxford) 49 2010 1900 1910
58. W. Zhang, N. Bansback, D. Guh, X. Li, B. Nosyk, and C.A. Marra Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis Journal of Rheumatology 35 2008 1729 1736
59. V. Bejarano, M. Quinn, P.G. Conaghan, R. Reece, A.M. Keenan, and D. Walker Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis and Rheumatism 59 2008 1467 1474
60. C. Han, J. Smolen, A. Kavanaugh, E.W. St Clair, D. Baker, and M. Bala Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis Arthritis and Rheumatism 59 2008 510 514 (Pubitemid 351563533)
61. A. Anis, W. Zhang, P. Emery, H. Sun, A. Singh, and B. Freundlich The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study Rheumatology (Oxford) 48 2009 1283 1289
62. R.F. van Vollenhoven, M.A. Cifaldi, S. Ray, N. Chen, and M.H. Weisman Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study Arthritis Care Research (Hoboken) 62 2010 226 234
63. J.S. Smolen, C. Han, H.D. van der, P. Emery, J.M. Bathon, and E. Keystone Infliximab treatment maintains employability in patients with early rheumatoid arthritis Arthritis and Rheumatism 54 2006 716 722
64. T. Olofsson, M. Englund, T. Saxne, A. Joud, L.T. Jacobsson, and P. Geborek Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study Annals of the Rheumatic Diseases 69 2010 2131 2136
65. R. Escorpizo, C. Bombardier, A. Boonen, J.M. Hazes, D. Lacaille, and V. Strand Worker productivity outcome measures in arthritis Journal of Rheumatology 34 2007 1372 1380 (Pubitemid 46898124)
66. R. Escorpizo, A. Cieza, D. Beaton, and A. Boonen Content comparison of worker productivity questionnaires in arthritis and musculoskeletal conditions using the International Classification of Functioning, Disability, and Health framework Journal of Occupational Rehabilitation 19 2009 382 397
67. D.E. Beaton, K. Tang, M.A. Gignac, D. Lacaille, E.M. Badley, and A.H. Anis Reliability, validity, and responsiveness of five at-work productivity measures in patients with rheumatoid arthritis or osteoarthritis Arthritis Care Research (Hoboken) 62 2010 28 37
68. W. Zhang, M.A. Gignac, D. Beaton, K. Tang, and A.H. Anis Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments Journal of Rheumatology 37 2010 1805 1814
69. M.V. Pauly, S. Nicholson, D. Polsky, M.L. Berger, and C. Sharda Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives Health Economics 17 2008 469 485 (Pubitemid 351517406)
70. M. ter Wee, W. Lems, H. Usan, A. van Gulpen, and A. Boonen The effect of biologicals on work participation in rheumatoid patients. A systematic review Annals of the Rheumatic Diseases 70 Suppl. 3 2011 710
71. V. Strand, and J.A. Singh Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity Drugs 70 2010 121 145
72. M.F. Drummond, M.J. Sculpher, and G.W. Torrance Methods for economic evaluation of health care programmes 2005 Oxford Medical Publications Oxford
73. R.F. van Vollenhoven, and J.L. Severens Observational studies: a valuable source for data on the true value of RA therapies Clinical Rheumatology 30 Suppl. 1 2011 S19 S24
74. S.E. Gabriel, P. Tugwell, and M. Drummond Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology Annals of the Rheumatic Diseases 61 2002 370 373 (Pubitemid 34257754)
75. C.A. Marra, N. Bansback, A.H. Anis, and K. Shojania Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis Clinical Rheumatology 30 Suppl. 1 2011 S9 18
76. J.A. Singh, R. Christensen, G.A. Wells, M.E. Suarez-Almazor, R. Buchbinder, and M.A. Lopez-Olivo A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview Canadian Medical Association Journal 181 2009 787 796
77. J.J. Caro, J. Moller, and D. Getsios Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13 2010 1056 1060
78. A. Briggs, and P. Fenn Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane Health Economics 7 1998 723 740 (Pubitemid 29012095)
79. A.H. Briggs, and A.M. Gray Handling uncertainty in economic evaluations of healthcare interventions British Medical Journal 319 1999 635 638 (Pubitemid 29414568)
80. K. Claxton, P.J. Neumann, S. Araki, and M.C. Weinstein Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease International Journal of Technology Assessment in Health Care 17 2001 38 55 (Pubitemid 32381740)
81. V. van de Velde, B. Pham, M. Machado, L. Ieraci, W. Witteman, and C. Bombardier Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review Arthritis Care Research (Hoboken) 63 2011 65 78
82. R. Goldbach-Mansky, J.M. Lee, J.M. Hoxworth, D. Smith, P. Duray, and R.H. Schumacher Jr. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis Arthritis Research 2 2000 145 153 (Pubitemid 32223719)
83. A. Finckh, N. Bansback, C.A. Marra, A.H. Anis, K. Michaud, and S. Lubin Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis Annals of Internal Medicine 151 2009 612 621
84. T.A. Hallinen, E.J. Soini, K. Eklund, and K. Puolakka Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting Rheumatology (Oxford) 49 2010 767 777
85. M. Vera-Llonch, E. Massarotti, F. Wolfe, N. Shadick, R. Westhovens, and O. Sofrygin Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists Journal of Rheumatology 35 2008 1745 1753
86. M. Vera-Llonch, E. Massarotti, F. Wolfe, N. Shadick, R. Westhovens, and O. Sofrygin Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate Rheumatology (Oxford) 47 2008 535 541
87. A. Kielhorn, D. Porter, A. Diamantopoulos, and G. Lewis UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug Current Medical Research and Opinion 24 2008 2639 2650
88. P. Lindgren, P. Geborek, and G. Kobelt Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden International Journal of Technology Assessment in Health Care 25 2009 181 189
89. K. Malottki, P. Barton, A. Tsourapas, A.O. Uthman, Z. Liu, and K. Routh Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Health Technology Assessment 15 2011 1 278
90. S. Merkesdal, T. Kirchhoff, D. Wolka, G. Ladinek, A. Kielhorn, and A. Rubbert-Roth Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure European Journal of Health Economics 11 2010 95 104
91. I. Cleemput, M. Neyt, N. Thiry, C. De Laet, and M. Leys Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions International Journal of Technology Assessment in Health Care 27 2011 71 76
92. M. Hoogendoorn, M.P. Rutten-van Molken, R.T. Hoogenveen, M.L. van Genugten, A.S. Buist, and E.F. Wouters A dynamic population model of disease progression in COPD European Respiratory Journal 26 2005 223 233 (Pubitemid 41079065)